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Abstract 
Background: The present study aims to examine the oxidative stress related activation of 
poly(ADP-ribose)polymerase (PARP), signs of parthanatos in circulating mononuclear 
leukocytes of patients with chronic heart failure (CHF) that was rarely investigated in the 
human setting yet. 
Methods: Patients with CHF (n=20) and age, body mass index matched volunteers (n=15) 
with normal heart function were enrolled. C-reactive protein, N-terminal pro-brain type 
natriuretic peptide (pro-BNP), plasma total peroxide level (PRX), plasma total antioxidant 
capacity (TAC), oxidative stress index (OSI), leukocyte lipid peroxidation (4-
hydroxynonenal; HNE), protein tyrosine nitration (NT), poly(ADP-ribosyl)ation 
(PARylation), and apoptosis inducing factor (AIF) translocation were measured in blood 
samples of fasting subjects. 
Results: Plasma PRX, leukocyte HNE, NT, PARylation and AIF translocation were 
significantly higher in the heart failure group. Pro-BNP levels in all study subjects showed 
significant positive correlation to PRX, OSI, leukocyte HNE, NT, PARylation and AIF 
translocation. Ejection fraction negatively correlated with same parameters. Among HF 
patients, positive correlation of pro-BNP with PRX, OSI and PARylation was still present.  
Conclusions: Markers of oxidative-nitrative stress, PARP activation and AIF translocation in 
blood components showed correlation to reduced cardiac function and the clinical appearance 
of CHF. These results may reinforce the consideration of PARP inhibition as a potential 
therapeutic target in CHF. 
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Introduction 
Heart failure as the outcome of a variety of cardiovascular diseases implies increasing 
burden for global healthcare systems.[1] Various pathophisiological conditons including 
ischemic heart disease, cardiomyopathies, myocarditis, long standing arrhythmias, metabolic, 
hematologic and genetic disorders may lead to impaired myocardial function [2,3]. The 
progression of cardiovascular dysfunction to heart failure is a complex phenomenon and 
involves the activation of numerous secondary pathways. 
Experimental and clinical studies provided wide range of evidence of increased 
oxidative-nitrative stress in heart failure.[2] The integrity of cardiac myocytes is deteriorated 
by reactive species damaging proteins, DNA and membrane lipids. The increased oxidative-
nitrative stress leads to the activation of various enzymes including matrix metalloproteinases 
and poly(ADP-ribose) polymerase-1 (PARP).  
Poly(ADP-ribose) polimerase 1 (PARP) is the major isoform of an enzyme family, 
with multiple regulatory functions. Upon activation, mainly by DNA single-strand breaks, it 
cleaves NAD+ into nicotinamide and ADP-ribose, forms long branches of ADP-ribose 
polymers and binds them to several nuclear target proteins (PARylation) [4]. PARP activation 
exerts its physiological and pathological effects via two principal mechanisms [5].  On one 
hand (i) it PARylates acceptor proteins including histones, transcription factors, and the 
PARP itself. PARylation contributes to DNA repair and to the regulation of gene expression. 
The protein expression of various proinflammatory mediators (citokines, chemokines, iNOS, 
ICAM-1) is regulated by PARP at the transcriptional level. On the other hand, (ii) oxidative-
nitrative stress-induced overactivation of PARP consumes NAD+ and consequently ATP, 
culminating in cell dysfunction and necrotic cell death. [3] 
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Poly(ADP-ribosylation) is activated under critical situations with oxidative-nitrative 
stress induced DNA damage, and was shown to play regulatory role in different cell death 
pathways, such as apoptosis, autophagy, necroptosis and parthanatos [6]. 
During caspase dependent apoptosis PARP-1 is cleaved by caspases preventing further 
loss of NAD+, providing energy for the apoptotic processes [7]. PAR accumulation can induce 
a form of caspase-independent death with triggering the translocation of mitochondrial 
factors, including apoptosis inducing factor (AIF). Pathogenic PAR polimer translocates to 
the mitochondria from the nucleus to mediate AIF release. AIF translocation to the nucleus 
promotes chromatin condensation and DNA degradation. This crosstalk between nucleus and 
mitochondria is the key point in special cell death pathway called parthanatos [8].  
The present study aims (1) to examine parthanatos phenomenon (oxidative-nitrative 
stress, PARP activation, AIF translocation) in blood components of patients with chronic 
heart failure, (2) to assess the possible correlation with the severity of the disease, and (3) to 
identify clinical parameters that may play role in the development of parthanatos of 
circulating mononuclear cells in chronic heart failure.  
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Materials and Methods 
Participants 
20 patients between the age of 50 and 70 years with known chronic heart failure 
(CHF) having clinically stable cardiopulmonary state (NYHA II-III) were enrolled at the 
Heart and Vascular Center of Semmelweis University, Budapest, Hungary. Heart failure was 
diagnosed according to the actual guideline of the European Society of Cardilogy (ESC) 
published in 2016. In accordance with the ESC guideline recommendations transthoracic 
echocardiography was used to evaluate cardiac structure and function and to measure left 
ventricular ejection fraction (EF) according to the modified Simpson’s rule (apical biplane 
method with tracing of endocardial borders). CHF diagnosis was verified by the reduced 
systolic function defined as ejection fraction (EF) below 40%. NYHA stages were also 
determined according to the ESC guideline. The etiology of the heart failure was divided to 
ischemic (having known ischemic heart disease (IHD), N=9) or non-ischemic (N=11) origin, 
without further evaluation [9]. Transthoracic echocardiography performed within the last 3 
months before enrollment was accepted if no significant change of patient condition was 
observed. In case of new symptoms, or lacking echocardiography in the previous 3 months, 
cardiac ultrasound was repeated. Volunteers matched by age, BMI, and cardiovascular risk 
factors (smoking, diabetes mellitus, hypertension and IHD) with normal systolic function 
served as controls (n=15). Exclusion criteria were insulin treated diabetes mellitus, acute 
coronary syndrome, stoke or major surgical intervention in the past 3 months, acute or chronic 
inflammatory diseases, and neoplasm.  
All procedures complied with the Helsinki Declaration of the World Medical 
Association and were approved by the institutional and regional ethics committee of 
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Semmelweis University (7268-0/2011-EKU). Written informed consent was acquired from all 
participants.  
Clinical examinations 
After enrollment, all participants completed an interviewer assisted questionnaire that 
included demographic (age, gender, and lifestyle) and general medical (medication, known 
illnesses, family history) inquiries. Current smoking was defined as one or more cigarette/day 
on a weekly average. Height and weight were measured on a calibrated stadiometer in light 
clothing. BMI was calculated as weight (kg)/(height(m))2. Transthoracic two-dimensional 
echocardiography was performed to detect left ventricular end diastolic diameter (LVEDD), 
left ventricular end systolic diameter (LVESD) and ejection fraction. Fasting blood samples 
were collected from all subjects for C-reactive protein (CRP), N-terminal pro-brain type 
natriuretic peptid (pro-BNP), oxidative-nitrative stress, PARP activity, AIF translocation 
measurements. CRP and pro-BNP levels were determined by immunochemical methods 
(Cobas Integra 400 Plus and Cobas E411 analyzers respectively; Roche, Basel, Switzerland) 
at the Central Laboratory of the Heart and Vascular Center of Semmelweis University.  
Ejection fraction, LVEDD, LVESD and plasma pro-BNP levels of individuals were 
used to characterize cardiac function. Brain natriuretic peptide (BNP) is a member of a family 
of human natriuretic peptides. Before its activation, BNP is stored as the precursor, pro-BNP. 
After pro-BNP is secreted in response to volume overload and resulting myocardial stretch, it 
is cleaved to the biologically inactive N-terminal fragment and the biologically active 
hormone BNP. The 2 fragments are secreted into the plasma in equimolar mounts, and both 
have been clinically evaluated for use in the management of congestive heart failure. The 
secreted N-terminal fragment is usually referred simplified as to plasma pro-BNP. According 
to newest guideline for the diagnosis and treatment of the heart failure of European Society of 
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Cardiology, elevated natriuretic peptides help to establish initial diagnosis, identifying those 
who require further cardiac investigation and patients with values below the threshold (125 
pg/mL) for the exclusion of heart failure. Natriuretic peptides are strong predictors of 
mortality in chronic heart failure and pro-BNP-guided therapies are showed to improve the 
outcome in heart failure [10-13].  
 
Oxidative-nitrative stress and PARP activation 
Plasma total peroxide level (PRX) was measured by Oxystat kit (Biomedica, Vienna, 
Austria) according to the user’s manual. Absorption was detected at 450nm by BioTek Power 
Wave XS Spectrophotometer (BioTek, BioTek Instruments, Inc., Winooski, VT, USA). PRX 
measurements are available from 11 control and 12 CHF patients. Total plasma antioxidant 
capacity (TAC) was measured by OxiSelect™ TAC Assay Kit (Cell Biolabs, San Diego) 
according to the user’s manual. Absorption was detected at 490nm by BioTek Power Wave 
XS Spectrophotometer. Results are given in CRE (µmol copper reducing equivalent). TAC 
measurements are available from 15 controls and 19 CHF patients. Oxidative stress index 
(OSI) is given as the ratio of total peroxide and TAC. For the determination of cellular lipid 
peroxidation, protein tyrosine nitration, PARP activation and AIF translocation, circulating 
mononuclear leukocytes were isolated by gradient centrifugation (Histopaque-1077, 
Sigma/Aldrich, St. Louis, MO, USA). Cellular lipid peroxidation, protein tyrosine nitration 
and PARP activation were estimated by immunohistochemical staining of methanol fixed 
leukocyte smears with rabbit polyclonal anti-4-hydroxynonenal (HNE) (Abcam, Cambridge, 
UK; 1:200, overnight, 4°C), rabbit polyclonal anti-nitrotyrosine (NT) (Millipore, Temecula, 
CA, USA; 1:80, overnight, 4°C), mouse monoclonal anti-PAR (Tulip, West Point, PA, USA ; 
1:500, overnight, 4°C), and anti-AIF rabbit polyclonal antibody (Millipore; 1:100, 4 °C, 
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overnight) antibodies. Measurements of AIF translocation are available 11 patients with CHF 
and 13 control subjects. 
Secondary labeling was achieved by biotinylated mouse and rabbit immunoglobulin 
specific antibodies (Vector Laboratories, Burlingame, CA, USA). Avidin – horseradish 
peroxidase complex and brown colored diamino-benzidine (DAB) (HNE) or black colored 
nickel enhanced DAB (NT, PAR, AIF) (Vector) was used to visualize specific labeling. Blue 
colored hematoxyilin (HNE) or red colored Nuclear Fast Red (NFR) (NT, PAR, AIF)  
(Sigma, MO, USA) was used as counterstain. Microscopic images of immunolabelled smears 
were acquired by Zeiss-Imager.A1 light microscope using 20x/0.45 and 40x/0.75 objective, 
AxioCam MRc5 camera and AxioVision – Rel. 4.8 software (Carl Zeiss Microscopy GmbH, 
Jena, Germany). The ratio of the positive cellular area and total cellular area (HNE area (%) 
and NT area (%)) or the ratio of positive nuclear area and total nuclear area (PAR area (%) 
and AIF are (%)) analyzing at least 300 cells per smear was calculated by computer-based 
evaluation (MBFImageJ, NIH, Bethesda, MA, USA). 
 
Statistical Analysis 
Sample size calculation was performed prior the recruitment of study subjects based 
on two measured parameters: PRX and PAR area. Standard deviation (SD) of these 
parameters were estimated using the data of our previous measurement among healthy human 
subjects (n=25) (unpublished data). The mean of PRX was 313.4 µmol/l with an SD of 118.5 
µmol/l. While mean of PAR area was 12.45% with an SD of 8.72%. Calculating 80% power 
for p<0.05, sample size of 15 was found to be eligible to detect 125.94 µmol/l and 9.3% 
change in PRX and PAR area respectively, which was decided to be sufficient to detect the 
expected change of 120 µmol/l and 10% in CHF patients [14].  
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Results are expressed as mean±SD for normally distributed variables and median 
[interquartile range] for non-normally distributed variables. Variables that violated the 
normality assumption (CRP, pro-BNP, HNE area, NT area, PAR area, AIF area) were log-
transformed before using them in the statistical models. Participants’ characteristics by study 
group were compared using two-tailed independent samples t-test. The distribution of 
categorical variables (gender, smoking, presence of diabetes mellitus, hypertension or IHD) in 
the different groups was compared by chi-square test. The possible relationship between 
clinical parameters and oxidative-nitrative stress, PARP activation, AIF translocation in the 
study cohort and among CHF patients was examined by Pearson’s correlation test and linear 
regression models. In case of multiple significant correlations in the CHF group, multivariate 
linear regression models were implemented. Missing values were treated as missing. In all 
cases p<0.05 was considered significant (SPSS 22.0 and Graphpad Prism and StatMate 
softwares).  
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Results 
Clinical parameters and anamnestic data 
In our study, 20 patients with chronic heart failure (CHF) and 15 controls were enrolled. The 
gender composition of the two groups was similar. Both age and body mass index of the two 
study groups were also comparable. There was no significant difference concerning the 
prevalence of hypertension, diabetes mellitus, ischemic heart disease, and smoking habit. The 
level of the inflammatory marker CRP was not significantly different in the study cohorts. 
Ejection fraction was significantly lower; LVEDD and LVESD were significantly higher in 
the diseased group. The level of pro-BNP was markedly increased in CHF patients. The 
median pro-BNP of control group is slightly elevated according to exclusionary cut-off point 
mentioned in the actual guideline of European Society of Cardiology (125 pg/mL), however 
these subjects showed no clinical signs of cardiac failure so the elevation of pro-BNP is most 
probably due to other conditions [9]. (Table 1.) In our CHF group patients having IHD do not 
differ in any above mentioned parameters from their non-IHD mates except from significantly 
reduced LVEDD (CHF without IHD: 68.6±10.6 mm vs CHF with IHD: 54.2±3.5 mm, 
p<0.05) and LVESD (CHF without IHD: 59.5±9.9 mm vs CHF with IHD: 45.4±3.8 mm, 
p<0.05). 
 
Oxidative, nitrative stress, PARP activation and AIF translocation in blood components 
Plasma PRX level was significantly increased in the CHF group indicating that these 
patients had more intensive oxidative stress compared to controls. On the other hand, TAC 
was not significantly elevated in CHF patients (p=0.066). After calculating OSI, we also 
found a non-significant elevation of this parameter among CHF patients (p=0.059). Similarly 
to PRX, cellular oxidative stress assessed by leukocyte HNE immunostaining intensity was 
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also significantly increased in the CHF group compared to controls. We observed significant 
(p<0.05) elevation in leukocyte NT staining intensity too, which may suggest an elevated 
nitrosative environment in CHF. The degree of PAR labeling in circulating mononuclear 
cells, reflecting the PARP activity in these cells, was significantly elevated in the disease 
group. Furthermore, in CHF group number of AIF-positive cells was significantly increased 
compared to the control group.  (Figure 1, 2.) 
 
Correlation of oxidative stress and signs of parthanatos with the indicators of cardiac function 
Examining the correlation between oxidative-nitrative stress, PARP activation, AIF 
translocation and the used indicators of cardiac function, such as ejection fraction and pro-
BNP levels in all study subjects revealed a significant positive correlation of the latter with all 
the following parameters; PRX level, OSI, leukocyte HNE, tyrosine nitration, PAR-ylation, 
AIF translocation. EF negatively correlated with same parameters: PRX, OSI, leukocyte 
HNE, tyrosine nitration, PARP activation and AIF translocation. The observed relationships 
may imply a negative correlation between cardiac function, oxidative-nitrative stress, PARP 
activation and AIF translocation. (Table 2, Figure 3. Panel A, C, E, G, I, K) Furthermore AIF 
translocation also (Log[AIFcell%]) positively correlated with LVEDD (R= 0.497, p<0.05). 
Further analyzing the same relationships in the CHF group only showed that plasma 
PRX level, OSI, and PARP activity in circulating leukocytes positively correlates with pro-
BNP levels of chronic heart failure patients suggesting a positive correlation between 
oxidative stress and PARP activation, and the actual clinical appearance of cardiac 
decompensation, the severity of the chronic heart failure. On the other hand, similar 
correlation was not observed in case of HNE, tyrosine nitration or AIF translocation (Table 2, 
Figure 3. Panel B, D, F, H, J, L). In the control group, however, there was no correlation 
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between oxidative stress and the signs of parthanatos and the indicators of cardiac function in 
the control group (data not shown). 
Still in the CHF group both LVEDD and LVESD negatively correlated with plasma 
PRX level and OSI (R= -0.819, p<0.01; R= -0.838, p<0.01 and R=-.0793, p<0.05; R=-0.817, 
p<0.01 respectively) where both LVEDD and LVESD negatively correlated to the presence of 
ischemic heart disease (R= -0.660, p<0.05; R= -0.673, p<0.05 respectively).  
 
Correlation oxidative stress and signs of parthanatos with anamnestic data and clinical 
parameters 
In the whole study cohort plasma PRX level and OSI positively correlated with the 
presence of ischemic heart disease (R=0.587, p<0.01; R=0.573, p<0.01 respectively), 
smoking habit (R=0.552, p<0.01; R=0.525 p<0.01 respectively). Leukocyte nitrative stress 
(log[NT area(%)]) positively correlated with type 2 diabetes mellitus (R=0.376, p<0.05).  
In the CHF group total plasma peroxide level and OSI positively correlated with the 
presence of ischemic heart disease (R=0.676, p<0.05; R=0.687, p<0.05).  
 
Determinants of oxidative stress in chronic heart failure 
According to our results plasma PRX levels and OSI in CHF patients positively 
correlated both with the pro-BNP levels and the occurrence of ischemic heart disease and 
negatively with the LVESD and LVEDD diameters. In order to estimate the role of these 
variables in the development of oxidative stress, multivariate regression was implemented. 
The analysis showed that serum pro-BNP and IHD are independent determinants of plasma 
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total peroxide level, and together they can explain the 97.7% of its variability. On the other 
hand, only serum pro-BNP was found to be the independent determinant of OSI. (Table 3.)  
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Discussion 
According to the results of both experimental and clinical studies, increased oxidative 
stress is characteristic for heart failure [3,4,15]. In some animal models positive correlation 
between myocardial level of reactive oxygen species (ROS) and ventricular dysfunction was 
observed [3]. Lipid peroxidation was also shown to be elevated in patients with hypertrophic 
cardiomyopathy and the level of oxidative stress was correlated to left ventricular dilation and 
systolic dysfunction [15]. Our results describing the increased plasma and mononuclear 
leukocyte lipid peroxidation among patients with CHF and the found correlation of plasma 
PRX with cardiac performance and pro-BNP levels correspond to and expend these previous 
findings. Although several experimental data provided evidence for the role of ROS in 
progression of heart failure, the results of clinical trials examining the possible beneficial 
effect of antioxidants – as vitamin C, vitamin A, co-enzyme Q – are controversial; attenuation 
of symptoms was reported in some cases, however in other studies neither the symptoms, nor 
the exercise capacity was improved. On the other hand it is also worth to point to the fact that 
some drugs already used effectively in the clinical management of heart failure may have 
antioxidant properties, which may play role in their therapeutic efficacy [4]. 
In our study cohort, plasma PRX level was also positively correlated to the occurrence 
of ischemic heart disease (IHD). The positive correlation with IHD could be observed both in 
the whole study cohort and in the isolated CHF group. The effect of acute ischemic episode of 
the heart on oxidative stress was previously examined in patients after acute myocardial 
infarction with or without cardiogenic shock, and increased oxidative stress was demonstrated 
in both cases [14,16]. According to our results, long-term, chronic ischemic environment may 
also induce further aggravation of plasma PRX levels in CHF patients. On the other hand, this 
change is also accompanied by increased plasma TAC, resulting a not significant elevation of 
OSI. 
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In our total study cohort, LVEDD and LVESD showed no correlation with PRX, 
however, in the isolated CHF groups cardiac dimensions negatively correlated with both total 
plasma peroxide levels and the presence of ischemic heart disease. The background of the 
negative correlation found between cardiac dimensions and total peroxide level is not yet 
clarified. Our observations that IHD among CHF patients is accompanied by elevated plasma 
PRX, but less increased cardiac diameters may explain this phenomenon. On the other hand, it 
is possible that ROS production is exhausted in the progress of excess cardiac remodeling.  
Several previous studies demonstrated the elevation of nitrative stress in various forms 
of acute and chronic heart failure both in experimental models and human biopsies [17]. 
Protein nitration is one of the characteristic reactions of the potent oxidant peroxynitrite 
formed in the spontaneous reaction of superoxide and nitric oxide. Increased nitration of 
sacro- endoplasmic reticulum Ca++ ATPase (SERCA) was reported in human hearts of dilated 
cardiomyopathy. SERCA inactivation by nitration may lead to the reduced function of the ion 
pump, hence compromising lusitropy as an early event in the development of CHF. [18] 
Furthermore overexpression of inducible NO synthase (iNOS) was demonstrated in human 
hearts with depressed contractility. iNOS-positive patients had larger left ventricular volume 
and depressed function, however the preserved NO generation was associated with higher 
cardiac work [19]. In our study significant elevation of protein nitration in circulating 
leukocytes was observed in the heart failure group. Additional pathophysiological alterations 
may have relevant impact on creation of nitrative stress. According to our observation protein 
nitration correlates with the presence of diabetes mellitus, which corresponds to previous 
findings showing that increased glucose concentrations or glucose fluctuations induce the 
production of nitrogen derived free radicals and oxidants, involving peroxynitrite, which in 
turn play important role in the pathogenesis of type 1 and type 2 diabetes mellitus and in their 
complications including cardiovascular morbidities [20].   
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Experimental studies provided increasing number of evidence of increased oxidative-
nitrative stress induced PARP activation in the development of cardiac dysfunction. Central 
role of PARP was observed in the pathogenesis of cardiac and endothelial dysfunction in 
animal models of streptozotocin induced and genetic diabetes mellitus [21]. The animal model 
of heart failure with chronic aortic partial occlusion was also found to be in associated with 
PARP activation [22]. The elevated activity of the enzyme was also observed in doxorubicin 
induced heart failure [23] and endotoxin (E. coli lipopolysaccharide: LPS) induced cardiac 
depression [24]. Despite of the high number of experimental publications fewer human or 
clinical studies were published. Molnar et al. provided evidence of oxidative stress and PARP 
activation in 8 human failing heart tissue samples derived from organs that were explanted 
during heart transplantation. But neither nitrotyrosine staining nor significant translocation of 
apoptosis inducing factor was presented [25]. In sepsis induced human heart failure 
significant PARP activation was detected by histological analysis of heart sections and the 
level of activation correlated to both troponin I and left ventricular systolic stroke work. [26]. 
Poly (ADP-ribosyl)ation in end-stage heart failure after left ventricular assist device 
implantation was detected in human myocardial biopsies [27]. One of the difficulties of 
establishing human studies examining the role of any parameter in the development of chronic 
heart failure is the limited availability of freshly isolated human heart tissue samples. 
According to our previous results activation of PARP in circulating leukocytes can be 
measured in PCI treated STEMI patients [14]. Moreover, Li L. et al. found that in human 
septic shock PARP activity of circulating mononuclear cells was strongly negatively 
correlated with ejection fraction and showed to be an independent risk factor of myocardial 
dysfunction [28]. Our present results confirmed the activation of PARP enzyme in human 
circulating leukocytes derived from patients with chronic heart failure and the level of 
activation correlated with severity of the disease. These findings may suggest that 
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investigating PARP activation in human circulating leukocytes may serve as an eligible 
method to describe systemic PARP activation with minimal invasive intervention. It may 
provide an adequate research or even clinical tool to examine the role of PARP activation in 
cardiac failure.  
According to recent findings, the activation of both heart hosted and circulating 
mononuclear cells can be observed in chronic heart failure independently of the etiology of 
CHF. The consequently evolving sustained pathological chronic inflammation plays 
important role in the pathogenesis of the disease. The unbalanced T and B cell activation 
described by various studies is shown to be associated with cardiomyocyte death, tissue 
remodeling and fibrosis that may lead to the progression of the disease [29]. The increased 
PARP activation in circulating mononuclear cells of CHF patients observed in our study may 
be involved in the activation of these cells. Therefore, PARP activation of these cells may not 
just follow the progression of CHF, but they may also contribute to its pathogenesis. 
Parthanatos is new definition based on more detailed results about PARP function in 
AIF translocation and caspase independent apoptotic cell death. In a mouse model of heart 
failure induced by aortic constriction translocation of AIF were attenuated by PARP 
inhibition [30]. Zhao et al. demonstrated that in experimentally induced congestive heart 
failure PARP and AIF protein expression levels were significantly higher than in the control 
group [31]. According to our previous results activation of PARP was followed by the 
translocation of AIF in PCI treated STEMI patients [14]. In another human study increased 
AIF protein expression and a trend of AIF translocation was observed in atrial tissues 
following cardioplegia and cardiopulmonary bypass [32]. Furthermore, Molnar et al. found no 
signs of AIF translocation neither in explanted failing hearts nor in control healthy donor 
hearts during their heart transplant studies [25]. In our present study we were able to show 
increased AIF translocation in circulating mononuclear cells of CHF patients. Moreover, the 
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level of AIF translocation correlated with markers of cardiac function (EF, pro-BNP) and 
ventricular end diastolic diameter. On the other hand, analyzing the CHF cohort revealed no 
such correlations. 
Our present results together with previous findings proved the presence of oxidative-
nitrative stress induced PARP activation and its deleterious consequences in chronic heart 
failure. The finding that these phenomena correlating with the actual cardiac function can be 
even observed in blood components may help to the better characterization of the actual 
significance of PARP activation and parthanatos in CHF. Additionally, further examinations 
may be required to clarify the source of these systemic alterations, their connection to cardiac 
function. The overall understanding of these changes may also strengthen the concept of 
PARP inhibitor treatment in CHF raised by several animal model studies. The pharmaceutical 
inhibition and the genetic deficiency of PARP were previously proven to be beneficial in 
various types of heart failure. In doxorubicin induced heart failure of mice treatment with the 
PARP inhibitor INO-1001 reduced mortality and cardiac depression [33]. The same inhibitor 
improved cardiac performance in aging animals and also promoted acetylcholine-induced, 
nitric oxide-dependent vascular relaxation [34]. Furthermore other PARP inhibitor PJ34 was 
shown to prevent Ca2+ overload and oxidative stress induced myocardial contractile 
disturbances in doxorubicin treated rats [35]. In a rat model of heart failure PARP inhibition 
with INO-1001 improved cardiac function after the permanent occlusion of the left anterior 
descending coronary artery [33]. In a similar mouse model INO-1001 prevented the decline of 
cardiac function, attenuated hypertrophy and tissue remodeling [30].  
Several contributors of cardiac hypertrophy have been previously identified, among 
others angiotensin II, which is recognized as one of the most potent stimulator of cardiac 
hypertrophy and remodeling. PARP deficient mice were shown to be protected from 
angiotensin II induced cardiac hypertrophy; and it was suggested that PARP contributes to the 
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angiotensin II induced signaling pathways leading to cardiac hypertrophy and failure [36]. In 
a spontanenously hypertensive rat model, the chronic inhibition of PARP with L-2286 
prevented remodeling, preserved systolic function and delayed transition of hypertensive 
cardiopathy to heart failure [37]. In a rat model of chronic heart failure induced by 
isoproterenol provoked myocardial infarction the effect of L-2286 was also investigated. The 
PARP inhibitor significantly reduced the progression of heart failure by reducing cardiac 
hypertrophy and interstitial fibrosis [38]. The anti-remodeling effect of L-2286 was compared 
to the efficacy of a widely used angiotensin converting enzyme (ACE) inhibitor, enalapril in 
the same experimental model. The PARP inhibitor was found to decrease the postinfarction 
myocardial remodeling even more effectively than enalapril treatment [39].  
Conclusion 
Our present study showed that components of parthanatos can be observed in the blood 
components of patients with chronic heart failure; oxidative-nitrative stress, PARP activation 
and AIF translocation also correlate to reduced cardiac function. Moreover oxidative stress 
and PARP activation may also indicate the progression of heart failure. The positive 
correlation between leukocyte PARP activation and pro-BNP may assign the minimal 
invasive measurement of this parameter to a possible diagnostic tool for heart failure 
progression monitoring. It may also serve as a potential early detection tool for incipient heart 
failure. Our data may also legitimate the further investigation of PARP inhibition, as 
therapeutic target in chronic heart failure.  
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Table 1. Clinical parameters and anamnestic data of study groups 
Control Chronic heart failure Sign. 
Number 15 20 
Gender: male/female 13/2 16/4 n.s. 
Age (years) 63.3±9.4 68.9±8.0 n.s. 
Body mass index 
(kg/m2 ) 
28.9±3.3 27.9±4.9 n.s. 
EF (%) 60.0±5.3 24.9±5.9 p<0.01 
LVEDD (mm) 48.2±4.6 63.0±11.1 p<0.01 
LVESD (mm) 31.4±5.1 54.0±10.6 p<0.01 
Pro-BNP (pg/mL) 148.4[47.9; 178.0] 2338.5[1475.6; 4597.5] p<0.01 
CRP (mg/L) 5.0[1.3; 6.1] 2.6[1.5; 4.9] n.s. 
Smoking (N) 1 3 n.s. 
Diabetes mellitus (N) 2 4 n.s. 
Hypertension (N) 13 19 n.s. 
Ischaemic heart 
disease (N) 
3 9 n.s. 
Statistical analysis: continuous variables are presented as mean±SD or median[IQR]in case of 
variables that violated the normal distribution, categorical variables are presented as the 
number of affected patients in each group. In order to test the possible differences between 
study groups T-test or chi-square test was performed. Sign, significance; N, number; n.s., non 
significant. 
Definition of abbreviations: EF, ejection fraction, LVEDD, left ventricular end diastolic 
diameter; LVESD, left ventricular end systolic diameter; Pro-BNP, N-terminal pro-brain type 
natriuretic peptide; CRP, C-reactive protein. 
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Table 2. Pearson correlation of oxidative-nitrative stress markers, PARP activity, AIF 
translocation with ejection fraction and pro-BNP levels.  
Statistical analysis: Pearson correlation was performed between continuous variables. In order 
to provide the normal distribution of variables that initially violated normality logarithmic 
transformation was implemented. R, Pearson coefficient; p, significance; N, number of cases 
in each calculation. 
All subjects CHF patients 
EF (%) 
log[pro-
BNP(pg/mL)] 
EF (%) 
log[pro-
BNP(pg/mL)] 
Total 
peroxide 
(µmol/L) 
R 
-0.458
0.531 -0.245 0.577 
p 0.028 0.009 0.444 0.049 
N 23 23 12 12 
TAC 
(µmol 
CRE) 
R -0.244 0.142 0.226 -0.412 
p 0.165 0.424 0.351 0.08 
N 34 34 19 19 
OSI 
(Total 
peroxide/
CRE) 
R -0.466 0.537 -0.339 0.630 
p 0.025 0.008 0.291 0.028 
N 23 23 12 12 
Log[HNE 
area(%)] 
R -0.682 0.628 0.336 0.331 
p 0.00002 0.0001 0.187 0.195 
N 32 32 17 17 
Log[NT 
area(%)] 
R 
-0.368 
0.497 -0.213 0.051 
p 0.032 0.009 0.381 .836 
N 34 34 19 19 
Log[PAR 
area(%)] 
R -0.466 0.576 -0.004 0.474 
p 0.006 0.000 0.986 0.047 
N 33 33 18 18 
Log[AIF 
cell(%)] 
R -,431 ,472 0.000 -,169 
p 0.035 0.020 0.999 0.620 
N 24 24 11 11 
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Abbreviations: pro-BNP, N-terminal pro-brain type natriuretic peptide; TAC: total antioxidant 
capacity; CRE: copper reducing equivalent; OSI: oxidative stress index; HNE: anti-
4hydroxynoneal;  NT, nitrotyrosine; PAR, poly(ADP-ribose); AIF, Apoptosis Inducing Factor 
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Table 3. Multivariate regression of the possible determinants of oxidative stress in 
chronic heart failure. 
Total peroxide (µmol/l) 
r2=0.977, pA<0.002, N=12 
OSI 
r2=0.978, pA<0.001, N=12 
B SD of B pB B SD of B pB 
Constant -1611.2 713.8 0.087 -2.629 0.927 0.047 
log[pro-BNP(pg/mL)] 991.7 154.5 0.003 1.402 0.201 0.002 
IHD 362.4 127.5 0.047 0.421 0.166 0.064 
LVEDD 26.3 25.7 0.362 0.059 0.033 0.151 
LVESD -55.2 30.2 0.141 -0.101 0.039 0.062 
Dependent variable was plasma total peroxide level (µmol/L), while independent variables 
were plasma pro-BNP, the occurrence of ischemic heart disease (IHD), LVEDD and LVESD. 
r2, coefficient of determination of the model; pA: significance level of the model, B: beta 
coefficient; pB: significance level of the effect of each independent variable. 
Abbreviations: OSI, oxidative stress index; pro-BNP, N-terminal pro-brain type natriuretic 
peptide; IHD, ischemic heart disease; LVEDD, left ventricular end diastolic diameter; 
LVESD, left ventricular end systolic diameter. 
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Figure 1. Parthanatos in blood components 
Panel A. Plasma total peroxide level. Data are presented as mean±SEM. Panel B. Total 
antioxidant capacity (TAC) Change in TAC values in the CHF and control group Data are 
presented as mean±SEM Panel C. Oxidative Stress Index (OSI) is given as the ratio of total 
peroxide and TAC. Data are presented as mean±SEM Panel D. Oxidative stress in 
circulating leukocytes. The percentage of positively labeled cellular area compared to total 
30 
cellular area was calculated on anti-4-hydroynonenal (HNE) immunostained leukocyte 
smears. Data are presented as median[IQR] Panel E. Nitrative stress in circulating 
leukocytes. The percentage of positively labeled cellular area compared to total cellular area 
was calculated on anti-nitrotyrosine (NT) immunostained leukocyte smears. Data are 
presented as median[IQR] Panel F. PARP activity in mononuclear cells. 
Immunohistochemical labeling of poly(ADP-ribose) (PAR), the end product of PARP was 
evaluated as described above. Data are presented as median[IQR]. Panel G. AIF 
translocation in mononuclear cells Immunohistochemical labeling of AIF. The percentage 
of positively labeled nuclei compared to total number of nuclei was calculated, Data are 
presented as median[IQR] 
*: p<0.05 
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ure 2.
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Representative microscopic image of anti-4-hydoxynonenal (HNE), anti-nitrotyrosine 
(NT), anti-poly(ADP-ribose) (PAR) stained leukocyte smears and AIF translocation. 
The brown (HNE) or black (NT, PAR, AIF) colored diamino-benzidine (DAB) represents 
specific labeling; the blue colored hematoxylin (HNE) or red colored nuclear fast red (NFR) 
(NT, PAR, AIF) was used for counterstaining. The microscopic images were taken by light 
microscopy using 40x/0.75 objective, the length of the scale bar is 50μm. The ratio of 
positively stained nuclear area is increased in CHF patients’ leukocyte smears stained against 
PAR and AIF. 
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Figure 3. Linear regression analysis of the relationship between oxidative-nitrative 
stress, PARP activity or AIF translocation with pro-BNP levels. 
Panel A. Linear regression of pro-BNP levels and plasma total peroxide in all subjects. Panel 
B. Linear regression of pro-BNP levels and plasma total peroxide in CHF patients. Panel C. 
Linear regression of pro-BNP and oxidative stress index in all subjects. Panel D. Linear 
regression of pro-BNP and oxidative stress index in CHF patients. Panel E. Linear regression 
of pro-BNP and leukocyte lipid peroxidation (4-hydroxynonenal; HNE) in all subjects. Panel 
F Linear regression of pro-BNP and leukocyte lipid peroxidation (HNE) in CHF patients. 
Panel G Linear regression of pro-BNP and leukocyte tyrosine nitration in all subjects. Panel 
H. Linear regression of pro-BNP and leukocyte tyrosine nitration in CHF patients. Panel I. 
Linear regression of pro-BNP and leukocyte PARyalation in all patients. Panel J. Linear 
regression of pro-BNP and leukocyte PARyalation in CHF patients. Panel K. Linear 
regression of pro-BNP and leukocyte AIF translocation in all subjects. Panel L. Linear 
regression of pro-BNP and leukocyte AIF translocation in in CHF patients. Increased pro-
BNP levels are accompanied with increased oxidative stress (PRX, OSI) and PARP activation 
of circulating mononuclear leukocytes either in the whole study cohort or in the CHF group 
alone. Lipid peroxidation, tyrosine nitration and AIF translocation in circulating mononuclear 
leukocytes however shows correlation with the pro-BNP levels only in the total study cohort. 
Continuous line represents the regression line, while dashed lines show the 95% confidence 
bends of the best-fit line. R2, coefficient of determination; p, level of significance. 
